No insurance, membership fee, or prior authorization is required, and HSA/FSA funds are eligible
An indirect comparison of data by Novo Nordisk from the STEP 1 trial and the SCALE trial of daily GLP-1 agonist liraglutide suggested 5.81% more weight loss with semaglutide than liraglutide at 68 weeks, and this was backed up by data from the STEP 8 trial, which directly compared the two treatments[1,3,4]
We partner exclusively with FDA-registered and inspected pharmacies for the shipping of these medications, ensuring quality and safety
GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity
The statistics cited (2-10x GH increase, 1.5-3x IGF-1 increase) are from published clinical studies
There is no aftercare, though eating and drinking within three hours is recommended